We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Immunoassay Screens Risky Malaria Blood Donations

By LabMedica International staff writers
Posted on 22 Aug 2013
An enzyme-linked immunosorbent assay (ELISA) has been used to screen blood donations in an area highly endemic for malaria. More...


The main causative agent of malaria, Plasmodium falciparum, poses a threat on critical transfusions for road accident victims, pregnancy-related hemorrhages and child anemia enhancing the risk of transfusion-transmitted malaria (TTM).

Scientists at the University of Strasbourg (Alsace, France) collected blood in ethylenediaminetetraacetic acid (EDTA) tubes from 2,515 voluntary blood donors in Benin, over a period of 10 months, from May 2009 and March 2010. Microscopic examination was used to count parasites and parasite density (PD) was expressed as the number of parasites per µL of blood.


The plasmodium lactate dehydrogenase (pLDH) antigen detection was performed by a sandwich ELISA notably an ELISA-malaria antigen test (apDianv; Turnhout, Belgium) that detects pLDH via immunocapture. The apDia Antigen ELISA is an in vitro diagnostic immunoassay (IVD) for the qualitative determination of Plasmodium spp. Antibody screening was performed using a homemade ELISA-antibody test.


Among the 2,025 males and 488 females screened, the rate of asymptomatic Plasmodium carriage was 295/2,515 (11.7%). Males had a higher infection rate of 12.4% than did females at 8.8%. Parasite density was very low with between seven and100 parasites per µL of blood reported in 80% of donors with parasitaemia. Three malaria species were diagnosed: P. falciparum in 280/295 patients (95.0%), Plasmodium malariae in 14/295 (5.0%), and Plasmodium ovale in 1/295 (0.34%). The use of a highly sensitive assay enabled pan Plasmodium pLDH detection in 966/2,515 (38.4%) and malaria antibody prevalence was found in 1,859/2,515 (73.9%).


The authors concluded that detection of the pLDH antigen seems to be an adequate screening tool in endemic areas, for this antigen indicates parasite presence. Routine screening of all donated blood would prevent infected blood donations and reduce P. falciparum transmission in critical patients, such as children and pregnant women. This tool would also decrease medical prophylaxis in donation recipients and contribute to lower Plasmodium resistance. One drawback was that if the donors had taken self-treatment measures prior to blood donation, malaria infection was masked and pLDH detection failed. The study was published on August 8, 2013, in the Malaria Journal.

Related Links:
University of Strasbourg
apDia


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Immunofluorescence Analyzer
IFA System
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The test combines RNA signals from the tumor-immune microenvironment to predict treatment response, rather than relying on a single marker such as PD-L1 expression.(Image Credit: Adobe Stock)

RNA-Based Test Predicts Immunotherapy Response in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the largest U.S. patient population eligible for immune checkpoint inhibitor therapy. Treatment selection often relies on PD-L1 expression, but a single protein... Read more

Immunology

view channel
Image Credit: Adobe Stock

Immune Profiling Identifies Early Maternal Autoantibodies Linked to Preterm Birth Risk

A typical pregnancy lasts about 40 weeks, but labor begins prematurely in roughly one in 10 pregnancies. Preterm birth is the leading cause of newborn death worldwide, yet its underlying causes and which... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NeoGenomics selected Indica Labs’ HALO AP platform to eable its digital pathology operations through a scalable, cloud-based framework (Photo courtesy of Indica Labs)

Expanded Partnership Scales AI-Powered Digital Pathology for Oncology

Oncology diagnostics rely on pathology and biomarker information to guide personalized treatment. As computational pathology and artificial intelligence (AI) expand insights from tissue analysis, laboratories... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.